Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Operating Leases (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Operating Leases for 6 consecutive years, with $24.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 8.24% to $24.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.7 million, a 8.24% decrease, with the full-year FY2025 number at $24.7 million, down 8.24% from a year prior.
  • Operating Leases was $24.7 million for Q4 2025 at PROCEPT BioRobotics, down from $25.2 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $49.2 million in Q4 2021 to a low of $829000.0 in Q2 2022.
  • A 5-year average of $25.0 million and a median of $26.3 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: tumbled 53.86% in 2022, then skyrocketed 3173.22% in 2023.
  • PROCEPT BioRobotics' Operating Leases stood at $49.2 million in 2021, then crashed by 53.86% to $22.7 million in 2022, then rose by 15.34% to $26.2 million in 2023, then grew by 2.62% to $26.9 million in 2024, then fell by 8.24% to $24.7 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Operating Leases are $24.7 million (Q4 2025), $25.2 million (Q3 2025), and $27.8 million (Q2 2025).